The Ewing's sarcoma family of tumours (ESFT) are diagnosed by EWS-ETS gene translocations. The resulting fusion proteins play a role in both the initiation and maintenance of these solid aggressive malignant tumours, suppressing cellular senescence and increasing cell proliferation and survival. EWS-ETS fusion proteins have altered transcriptional activity, inducing expression of a number of different target genes including telomerase. Up-regulation of hTERT is most likely responsible for the high levels of telomerase activity in primary ESFT, although telomerase activity and expression of hTERT are not predictive of outcome. However levels of telomerase activity in peripheral blood may be useful to monitor response to some therapeutics. Despite high levels of telomerase activity, telomeres in ESFT are frequently shorter than those of matched normal cells. Uncertainty about the role that telomerase and regulators of its activity play in the maintenance of telomere length in normal and cancer cells, and lack of studies examining the relationship between telomerase activity, regulators of its activity and their clinical significance in patient samples have limited their introduction into clinical practice. Studies in clinical samples using standardised assays are critical to establish how telomerase and regulators of its activity might best be exploited for patient benefit.
1. Introduction
Ewing's sarcoma family of tumours (ESFT)
The Ewing's sarcoma family of tumours (ESFT) include Ewing's sarcoma, peripheral primitive neuroectodermal tumours (pPNET) and Askin tumour. These solid tumours share similar histology, under the light microscope appearing as small round cells with regular nuclei surrounded by a narrow rim of clear or pale cytoplasm (Fig. 1) . Some tumours contain rosettes suggestive of a tendency towards neural differentiation, although these tumours are largely poorly differentiated. Ultrastructurally the tumour cells are primitive, with scant organelles and cytoplasmic glycogen pools or aggregates [1, 2] . The tumours arise in a number of different sites, most frequently in the bone (Ewing's sarcoma) or soft tissues (pPNET or Askin tumour). The ESFT of bone are thought to originate in the intra-medullary cavity rapidly progressing onto the cortex to produce a soft tissue component, whereas soft tissue ESFT often occur adjacent to the bone with no apparent intraosseous component or in isolated soft tissues. There is a peak incidence of diagnosis in young people between the ages of 10 and 24 years, affecting approximately 0.6 per million total population with a male to female ratio of 1.5:1. ESFT are not associated with familial cancer syndromes, although Caucasians are more frequently affected than Afro-Caribbean and Chinese populations [3] [4] [5] . The identification of non-random chromosome rearrangements between the EWS gene on chromosome 22q12 and a member of the ETS gene family is strong evidence for the common histogenesis of these tumours, and provides a valuable characteristic for their differential diagnosis from other small round cell tumours of childhood [6] .
Multi-agent chemotherapy, surgery, and radiation therapy have improved the 5 year progression-free survival (PFS) of newly diagnosed patients with localised disease to 70%. However, the 5 year PFS for patients who present with pulmonary metastases is 40% and for those with disease in the bone and/or bone marrow is b20%. Despite aggressive treatment regimens and improved local control therapy, recurrence and metastasis continue to pose the most difficult challenge for management and curative treatment of these solid cancers. Of the patients who relapse only 49-60% achieve partial or complete remission to second line treatment [7] [8] [9] [10] . These figures emphasise the urgent need for greater understanding of the molecular events that contribute to the development and maintenance of the ESFT malignant phenotype, to identify both biomarkers to improve selection and stratification of
EWS-ETS translocations and the transformed phenotype
ESFT are one of the few solid tumours for which the underlying molecular genetic abnormality has been described, that is rearrangement of the EWS gene on chromosome 22q12 with an ETS gene family member. These rearrangements have not been reported in normal cells. The most frequent translocation is the t(11;22)(q24;q12) which is described in 85% of tumours, resulting in the chimeric EWS-FLI1 fusion. Other EWS-ETS fusions have been described in the remaining 15% of tumours (Table 1) . These diagnostic translocations can be identified by conventional G-banding, although diagnostic accuracy is often improved using reverse transcriptase polymerase chain reaction and/or fluorescent in situ hybridisation (FISH) [11] [12] [13] (Fig. 1) .
The EWS-ETS fusion proteins contain the transactivating domain of EWS and the DNA binding domain of the corresponding ETS fusion partner (Table 1) . Consistent with the hypothesis that the EWS-ETS fusions are important for the development and maintenance of the ESFT malignant phenotype, expression of EWS-FLI1 in a proportion of NIH3T3 cells increases the ability of these cells to form tumours in soft agar or in immunocompromised mice [14, 15] , whereas decreased expression of EWS-FLI1 in ESFT cells in vitro appears to decrease proliferation [16] [17] [18] and reduce tumour growth and/or metastases in preclinical mouse models [17, [19] [20] [21] [22] . More recently EWS-FLI1 has been shown to suppress cellular senescence [23, 24] . The transforming activity of EWS-ETS fusions has largely been attributed to the altered transcriptional activity and targets of the EWS-ETS gene fusion proteins compared to those of the wild-type genes alone [14, [25] [26] [27] [28] [29] . A number of target genes are differentially induced or repressed during EWS-FLI1 dependent transformation [6] , although the detailed mechanism of transformation remains elusive. Since no single or group of gene(s) has yet been identified that reproduces the ESFT malignant phenotype it has been suggested that transcriptional activity may not be the only mechanism of EWS-ETS fusion-induced transformation. Consistent with this hypothesis, introduction of point mutations in the FLI1 DNA binding domain (preventing DNA binding) does not necessarily inhibit the transforming activity of EWS-FLI1 [30] . Furthermore some studies have suggested that the transforming activity of EWS-FLI1 might be attributed to modulation of RNA processing [31] [32] [33] . These observations are consistent with the hypothesis that the fusion gene alone is insufficient to cause overt ESFT, and that accumulation of secondary genetic events is essential for clinical manifestation of the transformed phenotype.
Secondary abnormalities
Although the EWS-ETS fusions are important for the development and maintenance of the ESFT malignant phenotype, secondary genetic abnormalities have been described in over 80% of tumours. Various numerical and structural aberrations have been identified, some of which are reported to be prognostically significant. Chromosome gain is more frequently described than chromosome loss, those patients presenting with more than 50 chromosomes having a significantly worse over-all survival rate [34] . A more complex karyotype has also been associated with a worse outcome [34, 35] . Although high-ploidy has been described in a small subset of tumours [36] , ESFT are usually diploid or near triploid [37] . Trisomies of chromosome 8 [38] [39] [40] [41] and 12 [39] are frequently described and associated (alone or in combination) with poor disease course and clinical outcome, although this has been disputed [34, 42] . Several other trisomies including 2, 5, 7, 14 and 21 have been reported, although there is no compelling evidence that these are of prognostic value. A number of structural imbalances have also been described, including the unbalanced translocation t(1;16) [35, [43] [44] [45] [46] , deletions of 1p36 [35, 39, 44] , 9p21 [34, 44, [47] [48] [49] [50] and gain of 1q [34, 51, 52] . Interestingly, the number of imbalances is generally reported to be more common in localised than metastatic tumours [39, 42] . However the clinical significance of many of these secondary abnormalities remains unclear, reflecting in part the small number of patients in which they have been systematically evaluated.
The most frequently described secondary genetic aberrations in ESFT are deletions of the CDKN2A locus on chromosome 9p, and abnormalities of genes that regulate the G1 cell cycle checkpoint. Although loss of the retinoblastoma gene product pRb is rarely described in primary ESFT [44, 49] , loss of the cyclin-dependent kinase (CDK) inhibitors p16, p21 WAF and p27 KIP1 (that bind to the CDK-cyclin D1 complexes preventing inactivation of pRb and consequently stopping G1/S transition) has been reported. Of these, deletion of CDKN2A exon 1α (which codes for p16) is the most frequently described, occurring in between 13 and 39% of primary ESFT [44, 47, 49, 50, 53, 54] . Although mutations in p21 WAF have not been described loss of expression is reported in 55-60% of tumours [49, 55] ; whether this is of prognostic significance remains to be seen. Loss or low expression of the cyclin-dependent kinase inhibitor p27 KIP1 has however been related to poor event-free survival [56] . Aberrations of p53 have also been described [44, 57, 58] , and although mutations of p53 are reported in only a small subset of primary ESFT (b10%) in these patients they are associated with a poor prognosis [48, 55, 59] . However, most tumours express wild-type p53, high levels of which in primary tumours appear to be an indicator of poor outcome [60, 61] .
ESFT signatures and cell of origin
Genome-wide analysis of primary ESFT has identified tumour specific gene signatures that can distinguish ESFT from other bone and soft tissue cancers [62] [63] [64] [65] [66] . It is anticipated that these profiles will elucidate common molecular pathways that are responsible for the ESFT phenotype [67] , and may identify common targets for the development of novel therapeutics.
Recent profiles of tumours [68] and model systems of ESFT [63] suggest that ESFT may arise in as yet poorly defined mesenchymal progenitor cells. Consistent with this hypothesis, knock-down of EWS-FLI1 in ESFT cells results in a gene expression profile that more closely resembles the mesenchymal stem cell than the original ESFT cell [69] . Furthermore expression of EWS-FLI1 in human bone marrow-derived mesenchymal progenitor cells induces transformation to generate cells that grow tumours that resemble ESFT histologically in nude mice [70, 71] .
Early studies favour a primitive neural crest cell as the putative cell of origin, based largely on immature tumour neural phenotype and the potential of some cells for neural differentiation [72, 73] . As these tumours are predominantly cholinergic [74, 75] , they may arise from postganglionic parasympathetic primordial cells which are located throughout the parasympathetic autonomic nervous system. The wide distribution of these pluripotent stem cells is consistent with the variety of soft tissue and bony locations in which ESFT are found. More recently the expression of EWS-FLI1 in neural crest stem cells has been shown to disrupt normal neural crest development [76] , providing further support that neural crest stem cells may be the cells of origin for this aggressive malignant tumour. However expression of the EWS-ETS fusions can also induce transformation of fibroblasts [14] , haemopoietic cells [77] and cells derived from primary bone [78] , demonstrating that although the transforming activity of the EWS-ETS fusion may be dependent on cellular context this is not strictly limited to a primitive mesenchymal or neural cell milieu. Furthermore the capacity of the EWS-FLI1 fusion to induce a neurosecretory-phenotype in mesenchymal-derived NIH 3T3 cells Table 1 Non-random EWS gene rearrangements identified in bone and soft tissue sarcomas a. Translocation of the EWS gene on chromosome 22q12 with a member of the ETS family of transcription factors is diagnostic of ESFT (shown in bold). Additional rearrangements of the EWS gene and alternative translocations described in other sarcomas are shown. b. The EWS breakpoint on chromosome 22q12 is usually constant, but the breakpoint within the partner ETS gene family member can vary. The most frequently described abnormality in ESFT is the t(11;22)(q24;q12) leading to the EWS-FLI1 type 1 gene fusion transcript; this is generated from the first seven exons of EWS joined to exons 6-9 of Fli1. Detectable telomerase activity = not significant [81, 156] Detectable hTERT protein levels = not significant [86] High telomerase activity = not significant [157] Detectable telomerase activity in 12.5% of primary tumours and 100% metastases; high telomerase activity = poor prognosis [82] Peripheral blood High telomerase activity and high hTERT expression in follow-up = poor prognosis [81] 
Neuroblastoma
No Telomerase Tumour Short telomeres = good prognosis [158] High telomerase activity = poor prognosis [152, [158] [159] [160] High hTERT and hTR levels = poor prognosis [152] High WT hTERT levels = poor prognosis [161] Low hTR levels and low telomerase activity = good prognosis [162] Detectable telomerase activity at diagnosis or end of treatment = poor prognosis [ [185, 186] High telomerase activity = poor prognosis [187] High telomerase activity = recurrence rate [188] hTERT detected = poor prognosis [189] High hTERT = poor prognosis [190] Non small cell lung carcinoma (NSCLC)
No Telomerase Tumour Telomerase activity = poor prognosis [191, 192] Telomerase activity and high hTERT expression = poor prognosis [193] Short telomeres = poor prognosis [194] 
Gliomas
No Telomerase + ALT (16-25%) [195, 196] Tumour High telomerase activity = poor prognosis [197] Focal hTERT = poor prognosis [198] hTERT MNS16A genotype = no correlation with prognosis [199] hTERT MNS16A SS genotype = better prognosis [200] ALT phenotype = better prognosis [195, 196] Yes (APL-RARα) Telomerase PBMC Short telomeres = poor prognosis [87] High telomerase activity = poor prognosis [87] (continued on next page) (continued on next page) [79] makes the identification of the cell in which ESFT arise even more challenging, since the limited neural phenotype associated with some ESFT might not reflect the cell of origin but rather be a consequence of the transforming EWS-FLI1 fusion. The cell, or indeed cells, in which ESFT arise therefore currently remain(s) elusive.
Telomerase and regulation of its activity in ESFT
Telomerase activity is up-regulated by the transcriptional activator EWS-FLI1 [80] , the most frequently described primary gene alteration that characterises ESFT. It is therefore unsurprising that telomerase activity has been detected in both primary ESFT samples [81] [82] [83] and ESFT cell lines [80, [83] [84] [85] . The detection of the human telomerase reverse transcriptase (hTERT) catalytic subunit of telomerase in primary ESFT by immunohistochemistry is consistent with these observations [86] . However, neither telomerase activity nor expression of hTERT has been reported to predict outcome in patients with ESFT [81, 86] . One study has described higher levels of telomerase activity in metastatic lesions of ESFT compared to levels in tumours at diagnosis [82] , though the proportion of positive primary tumours in this study was much lower (12%) than that reported in other studies (70% [83] and 84% [81] ). Although this requires further investigation, increased telomerase activity in metastatic secondary lesions compared to that in tumour at diagnosis would be consistent with the hypothesis that tumours continually select for incrementally higher levels of telomerase activity as they proliferate and acquire genetic changes associated with invasive cancer [87, 88] .
Although telomerase activity is not prognostic in primary tumour, in a small group of patients consistently high telomerase activity in peripheral blood taken during follow-up correlated with a reduced progression-free survival compared to that in patients where telomerase activity was low or became low after treatment [81] . Telomerase activity measured in peripheral blood from patients with ESFT may arise from disseminating ESFT cells. Indeed Ohali et al. [81] reported a good correlation between telomerase activity and the presence of disease detected by RT-PCR for EWS-ETS fusion transcripts, suggesting that telomerase may be a useful marker of minimal residual disease. However the reduced sensitivity of ESFT cell detection using telomerase activity (1 ESFT cell in 1 × 10 4 normal cells) compared to that of RT-PCR for EWS-ETS fusions (1 cell in 1 × 10 6 normal cells) and discordance between telomerase activity and RT-PCR for EWS-ETS fusions in peripheral blood from some patients [81] , does not support this hypothesis. Nevertheless high telomerase activity, arising from ESFT cells in peripheral blood taken from patients on follow-up, may be a useful marker of response and clinical course independent of minimal disease status. In vitro studies have shown that the chemotherapeutics doxorubicin [85] and imatinib [89] down-regulate telomerase activity in ESFT cell lines, consistent with the hypothesis that changes in telomerase activity and/or factors regulating this activity may be useful biomarkers of response to therapy during treatment and follow-up. The imatinib-induced decrease in telomerase activity is associated with induction of cell cycle arrest, although the mechanism of action is unclear [89] . The hypothesis that changes in telomerase activity within haemopoietic compartments might reflect tumour burden or be a useful biomarker of response measured in peripheral blood mononuclear cells is not new (Table 2) . However these possibilities require further investigation in prospective quality controlled clinical trials, with relevant controls to account for the variability in telomerase activity within peripheral blood mononuclear cells from non-treated age-matched controls. Telomerase activity in ESFT cells is most likely increased through EWS-FLI1 dependent up-regulation of hTERT, either directly [80] or indirectly through a target gene such as MYC-C which activates the hTERT promoter [90, 91] and is itself up-regulated by EWS-FLI1 [25, 92] (Fig. 2) . However increased copy number of the genes encoding components of the telomerase pathway, such as the regulatory human telomerase RNA (hTR) and hTERT genes located on chromosomes 3q26.3 and 5p15.33 respectively, might also be responsible for the up-regulation of telomerase activity in ESFT. Consistent with this idea trisomy of chromosome 5 has been reported in 15% [34] and gain of 5p in 20% [65] of primary tumours, although one study has failed to identify gain of 3q or 5p in 20 primary ESFT [38] . Chromosomal gains and gene amplifications involving chromosome arms 5p and 3q are among the most frequently described in human tumours, and increased gene dosage of the telomerase regulatory genes hTERT and hTR has been described and associated with clonal evolution in a variety of cancers, suggesting that this provides a growth advantage for these cells [93] .
Tumour microenvironment might also influence the activity of telomerase in ESFT, since like most solid tumours the ESFT microenvironment is heterogeneous with areas of hypoxia reflecting the abnormal vasculature network and high proliferation rate of the cells [94] . Hypoxia-induced stabilisation of hypoxia-inducible factor-1 (HIF-1) is reported to increase telomerase activity through several mechanisms including up-regulation [95, 96] or alternative splicing [97] of hTERT mRNA, up-regulation of hTERT protein [96, 98] or up- [206] Telomerase activity = no correlation with remission rate [207] hTERT level = no correlation with remission rate in childhood leukaemia [208] Telomerase activity = no correlation with remission rate in adult AML [209] High telomerase activity = better remission rate [210] BM High telomerase activity = poor prognosis in pediatric patients [207] High hTERT = good prognosis in childhood ALL [208] regulation of hTR [97] . Although it is not known whether HIF-1 directly influences the transcriptional activity of the EWS-ETS protein, the CREB-binding protein p300 promotes HIF-1 transcriptional activity [99] and also cooperates with EWS-ETS in the initiation complex of TERT transcription [80] , implying that hypoxia may influence telomerase activity in ESFT. Furthermore the alternative splice variants (wild-type, α-, β-, α-β-) of hTERT are differentially expressed in ESFT cell lines in hypoxia and normoxia, suggesting that alternative splicing of the hTERT gene may regulate telomerase activity in ESFT cells as described in other systems [100] [101] [102] [103] [104] (Fig. 2) .
Telomere maintenance in ESFT
ESFT are reported to express and utilise telomerase to maintain telomere length [83] . However despite the presence of functional telomerase, telomeres in ESFT are frequently shorter than those of matched normal cells [83, 105, 106] . Therefore, although telomere stabilisation is a requisite step in tumorigenesis the shortening of telomeres must occur at some point in ESFT development. When this shortening takes place and whether it occurs in telomerase positive or negative cells is not clear. Since critically shortened telomeres have been described in precancerous lesions [88, 107, 108] and in patients with Fanconi anaemia that have an increased susceptibility to develop cancer [109] , it seems likely that telomere shortening is an early event driving the development of ESFT. Therefore the short telomeres may be a consequence of rapid proliferation prior to activation of telomerase. In this model ESFT may arise in telomerase negative cells by generation of the EWS-ETS translocations, which drive proliferation resulting in the development of shortened telomeres leading to chromosome instability, crisis, and subsequently activation of telomerase to stabilise the telomere and suppress cellular senescence (Fig. 3) . Consistent with the idea that EWS-ETS play a role in the maintenance of the ESFT malignant phenotype through maintenance of telomere length, EWS-FLI1 is reported to up-regulate telomerase activity [80] and prevent cellular senescence [23, 24] . This hypothesis is consistent with the concept that chromosomal instability underlies the generation of changes in the chromosome and generation of genomic heterogeneity, to maintain proliferation and drive development of the malignant phenotype during tumorigenesis. Of course it may be that ESFT arise in cells that express telomerase but that this is insufficient to maintain telomere length in the rapidly dividing transformed cells, resulting in EWS-ETS dependent upregulation of telomerase to stabilise the telomere at an albeit shortened length. Both of these possibilities suggest that telomerase-mediated stabilisation of telomeres is not an early event in tumorigenesis, and are supported by observations that EWS-ETS Fig. 2 . Potential sites of telomerase regulation in ESFT. The hTERT gene is regulated by numerous transcription factors acting on the promoter. EWS-ETS fusion transcripts can complex with CBP/p300 leading to up-regulation of both hTERT transcription and telomerase activity (⁎it is not clear if it has the same effect on hTR). There is also an ETS binding site in the hTERT promoter which may be the target for some fusion proteins (⁎⁎). Different ETS family members may also confer altered interactions with the hTERT promoter on EWS-ETS fusions [80] , which may include adjacent binding sites like AP-1 although this possibility requires investigation. The up-regulation of MYC-C by the EWS-ETS fusions may also in turn promote hTERT and hTR transcription through the promoter E-box sites [25, 92] . HIF-1 can also act at the hTERT and hTR promoters, relevant in areas of hypoxia within ESFT [94] . Alternative splicing is an important regulatory mechanism for the hTERT gene and all of the major mRNA isoforms are present in ESFT cells in vitro (Proctor, unpublished observations). The alpha splice variant has a dominant negative action on telomerase [100, 232] although it is not clear whether regulation by splicing takes place at the RNA or protein level ( †).
fusion-induced tumorigenesis is dependent on permissive cellular environment. Whether the ESFT precursor cell has shortened telomeres resulting in genetic instability leading to translocation of the EWS gene, or whether the EWS-ETS translocations arise in precursor cells inducing genetic instability resulting in shortened telomeres, up-regulation of telomerase activity and accumulation of secondary genetic abnormalities remains to be seen. Increased understanding of the relationship between secondary genetic changes, genome instability, tumour progression and the identification and characterisation of the cell(s) in which ESFT arise will inform the development of these hypotheses.
Those patients that present with ESFT in which the telomeres are shorter compared to those with unchanged or longer telomeres are reported to have a 5-fold increased risk of relapse [105] . Whether abnormal shortened telomeres and accumulation of G1 cell cycle checkpoint defects in ESFT predict a worse outcome is not know, although it is interesting to speculate that together these may predispose cells to unbalanced chromosome segregation at cell division and development of a more complex genotype. However, levels of telomerase activity in ESFT at diagnosis are elevated but do not correlate with telomere length and are not predictive of outcome [81, 105] . These data might be taken to suggest that telomere length is not dependent on telomerase activity in ESFT. However it is most likely that telomerase has a fundamental telomere-dependent role in the initiation of tumorigenesis (described above), and subsequently plays both telomere-dependent and -independent roles in the progression and maintenance of the malignant phenotype [110] .
Clinical utility; potential, challenges and reporting
Increasing evidence that dysfunctional telomeres play a causal role in the process of malignant transformation has made them attractive as potential biomarkers for early cancer diagnosis and prognostication. That abnormally short telomeres are prevalent at the premalignant stage also raises the interesting possibility that avoidance or reversal of the malignant phenotype by interfering with factors that regulate telomere length could be a potential strategy for cancer chemoprevention. Since the majority of tumours appear to rely on telomerase to maintain telomere length for immortalisation and genomic stabilisation, this enzyme is an attractive target for the design of novel cancer therapeutics [111] [112] [113] . Recent studies demonstrating telomere independent tumour-enhancing activities of telomerase [114] make it even more appealing as a target. Although the role of telomerase and telomere dynamics in normal and cancer cells is not fully understood, it is anticipated that increased understanding of these processes will allow for their more precise exploitation for therapeutic advantage.
Even though much about telomere biology and the plethora of proteins that play roles in maintenance of telomere length remain unclear, several proof of principal studies have demonstrated that telomere length, telomerase activity and in some cases the potential regulators of its activity hTR and hTERT may be of predictive and/or prognostic value (Table 2 ). The key advantage of these as biomarkers is that they are features of most cancer cells (including putative cancer stem cells), and critical for the development and progression of these malignancies. However uncertainty about the significance of telomere length and of low or transient expression of telomerase and regulators of its activity in normal biology compared to cancer patho-physiology has slowed their introduction into clinical practice. This highlights the importance of investigating these factors in paired tumour and normal samples, and evaluating the impact of tumour heterogeneity on their potential clinical significance. These studies will benefit from analyses in specific cancer and normal cell populations, and an evaluation of the impact that proliferation and cell cycle-dependent regulation of telomerase activity will have. The use of in situ assays to detect telomerase activity [115, 116] and hTERT mRNA [117] [118] [119] , or Fig. 3 . Telomere biology and telomerase in ESFT. ESFT contain EWS-ETS fusions, have shortened telomeres and increased levels of telomerase activity. It is unclear whether telomere shortening leads to increased genetic instability to facilitate the formation of the EWS-ETS translocation or whether the EWS-ETS fusion is the initiating event that drives cell proliferation resulting in telomere shortening. What is clear is that the EWS-ETS fusions and factors like hypoxia and MYC-C are important in the reactivation of telomerase, which along with acquired abnormalities in cell cycle regulators allow ESFT cells to avoid senescence and stabilise the shortened telomeres. Continued cell division in the presence of shortened telomeres is permissive to the acquisition of further oncogenic changes, which contribute to the development and maintenance of the cancer phenotype.
technologies such as laser capture microdissection [120, 121] or cell sorting [122] [123] [124] [125] to isolate specific cell populations prior to assays for telomerase or regulators of its activity will facilitate these studies. Failure to define the clinical utility of these markers also reflects the small patient numbers in individual studies and lack of standardisation of assays and reporting, emphasising the importance of prospective studies utilising standardised assays. Such studies demand that an assay is robust, reproducible, sensitive, and specific (Fig. 4) , and that standardisation is established from sample collection, transfer and storage in the laboratory, through to analysis and data reporting.
In this final section we have discussed some of the fundamental practical and technical challenges of evaluating telomere length, hTR, hTERT and telomerase activity in clinical samples.
Telomere shortening in tumour compared to adjacent non-tumour or peripheral blood is attractive as a prognostic marker as the assays are performed on DNA which is relatively stable and readily isolated from tissues. This may also be informative in different cancer types (Table 2) , regardless of the mechanism of telomere maintenance. Telomere length is traditionally measured by determination of a mean telomere restriction fragment (TRF) length. This requires restriction enzyme digest of genomic DNA (~1 μg) from tumour and a paired normal tissue, Southern blot and hybridisation to a probe for the telomeric repeats (TTAGGG) n . This method is most informative when DNA is extracted from fresh frozen tissue comprising purely tumour or normal cells, overcoming the heterogeneity of tumours and providing cancer cell specific estimations of telomere length and not an average telomere length from a mix of normal and cancer cells. However sufficient amounts of this precious resource are not always available, especially when cancers are diagnosed by small needle biopsies and in rare cancers such as ESFT. Therefore alternative methods for the measurement of telomere length have been developed (Table 3) . Most useful has been the development of a quantitative assay utilising the polymerase chain reaction (PCR), which has the advantage that it can be performed in amounts of DNA (~200 ng) that can be isolated from small numbers of pure cell populations. This assay is also robust, quantitative, rapid and amenable to high throughput [126] [127] [128] . Most studies of telomere length have focussed on the measurement of average telomere length in tumour compared to normal cells. However this may not be as informative as analysing telomere length of individual chromosomes, since it may be that attrition of specific chromosomes (and dysfunction of the genes which they carry) will initiate the malignant process. Single telomere length analysis (STELA) has identified large-scale differences in telomere length throughout development [129] , as well as a class of extremely short telomeres in human cancer cell lines [130] . However, the biological and clinical significance of specific telomere shortening in both normal and cancer cells requires further investigation. Currently STELA has only been developed to analyse telomere length of a limited number of chromosomes including chromosomes 2p, 11q, 12q, 17p and the sex chromosomes [129, 131] , although there is the potential to develop the technique to examine telomere length in all chromosomes.
Telomerase is the enzyme, which together with telomerebinding proteins, appears to be essential for the immortalisation of most human cancer cells. However the initial expectation that telomerase activity would be a universal specific marker of malignancy has not been realised and its potential clinical utility remains unresolved.
Telomerase activity is most widely measured in clinical samples using the PCR based telomerase repeat amplification protocol (TRAP) assay [132] , or adaptations of this protocol. The assay measures the telomerase-dependent addition of (TTAGGG) n repeats to the end of a synthetic primer with a telomere-like sequence (TS primer). The extended oligonucleotide products are then amplified by PCR and the amplified DNA band products (6 bp apart) are separated by polyacrylamide gel electrophoresis and typically visualised by autoradiography. Semi-quantitative evaluation relative to an internal The 'Gold standard' method for measurement of TA.
Quantification is not accurate. [132] [133] [134] [135] [136] Suitable for analysis of frozen tumour, BM, PB, and body fluids including urine and bile. For BM, PB and fluids white blood cells must be purified prior to protein extraction.
Relatively time consuming.
No need for specialist equipment.
Analysis requires 6 μg protein.
TA is an average of all cells analysed including any contaminating normal cells.
ELISA based TRAP assay
Adaptation to the TRAP assay, an ELISA replaces the gel electrophoresis stage.
More simple and quicker than the standard TRAP assay.
Quantification is still post PCR therefore not accurate.
[121]
Sensitivity and intra-assay variability is comparable to the standard TRAP assay. standard is possible using densitometry; the method of detection depending on the label used e.g. phosphoimager [133] , fluoroimaging [134] or in-gel staining with SYBR Green ™ [135, 136] . Each assay includes a series of controls to validate the data including a negative control (pretreatment of the samples with heat or RNase A) and a positive control cell line. This assay is highly sensitive, reportedly detecting telomerase activity in as few as 10 immortal cancer cells [137] . With this sensitivity telomerase activity has been detected in some normal somatic cells [138] [139] [140] and in several benign tumours [140, 141] . Usually telomerase activity is higher in immortalised cancer cells than in these normal somatic or benign cancer cells. However to evaluate and compare telomerase activity between normal and cancer cells a reliable method of quantification, with a common reporting standard is needed. More recently telomerase activity has been measured using a real-time quantitative TRAP assay which requires smaller amounts of clinical material, important when analysing small numbers of isolated tumour, tumour stem cells or normal cells from valuable clinical material (Table 3) . Real-time TRAP also enables a more accurate quantification of telomerase activity, and with the inclusion of standardised telomerase reference materials may be useful to define the threshold of telomerase activity attributed to non-cancerous cells and so better evaluate clinical relevance [142] . hTERT and hTR are two major components of the active telomerase complex, and have been investigated as surrogate markers of telomerase activity. Expression of hTERT mRNA and protein appears to be more restricted than expression of hTR RNA which is detected in all cell types; a protein product of hTR has not been described. All are frequently over expressed in tumours compared to normal cells, and may be prognostic or predictive of outcome in some cancer patients (Table 2) . Furthermore hTERT profiles may be predictive of response to some therapeutics [143, 144] . Measurement of these regulators might therefore predict patient response to a drug, assess efficacy of treatment or monitor disease status to predict relapse. hTERT has been widely described as a major regulator of telomerase activity [145, 146] , and a correlation between hTERT and telomerase activity has been reported in several different cancer types including ESFT [81] . This has made hTERT the most widely used surrogate marker for telomerase activity. However, hTERT mRNA has several splice variants some of which are inactive and competitive inhibitors of hTERT driven activation of telomerase activity (Fig. 2) . These are also expressed in cells that do not express telomerase activity suggestive of a telomerase-independent activity [147] . There is increasing evidence that hTR is also over expressed in tumour compared to normal cells where it may play a role in telomere maintenance, regulation of telomerase activity [148] [149] [150] [151] and predict prognosis [152] . High levels of hTR have also been described in tumours that utilise ALT to maintain telomere length [153] , suggesting that hTR, like hTERT, has telomerase-independent activity. Consequently this may be an informative biomarker regardless of the mechanism of telomere maintenance.
As biomarkers hTERT and hTR are attractive as they can be measured using the high through put sensitive quantitative reverse transcriptase (RT)-PCR, and may be informative in readily accessible clinical materials such as washings, brushings, fine needle aspirations, peripheral blood and urine. Using quantitative RT-PCR the sensitivity of hTERT detection is 9-10 malignant cells [154] ; (Brownhill, unpublished observations), whereas hTR can be detected in a single cell (Brownhill, unpublished observations) consistent with its higher expression levels. However, defining their clinical utility has been hampered by their expression in normal cells, low copy number per cell (hTERT) and lack of consensus about their relationship with telomerase activity and the role they play in tumorigenesis. As with TRAP assays [155] within a clinical setting, quantitative RT-PCR may be useful to determine a threshold of normal expression and so define levels relevant to disease status and outcome. Studies in patient samples have not systematically examined the relationship between telomerase activity, hTERT and its isoforms and hTR (Fig. 2) and their clinical significance. These studies are critically important to establish how these factors might best be used to inform management of patients with cancer. The TRAPeze XL is a commercially available kit for and ELISA based TRAP assay but has been adapted for real-time analysis and involves inclusion of a fluorescent probe in the PCR reaction.
The kit provides a standard that can be used in assays therefore allowing standardised reporting of results.
Real-time PCR system needed [227] [228] [229] [230] [231] Reported to have an increased specificity compared to the incorporation of SYBR green.
It is suggested that an internal control is used to normalise TA during amplification however it has been reported that the internal control reduced rather than improved the correlation coefficient.
Improved reliability, assay time and accuracy of quantification compared to the standard TRAP assay. Suitable for analysis of tumour, BM, PB, and body fluids including urine and bile. For BM, PB and fluids white blood cells must be purified prior to protein extraction. Analysis is possible with only 1000 cells or 500 ng protein.
Tumour specific telomere length possible if tumour cells are isolated by laser capture microdissection.
A number of different techniques have been used to determine telomere length and telomerase activity. This table identifies these techniques and details their advantages and disadvantages including their suitability for the analysis of clinical samples.
